TapewireFind a company

person · Reporting owner

MUSSALLEM MICHAEL A

Disclosed activity across 1 company

Tapewire entity
91594
SEC CIK
0001204551

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Edwards Lifesciences CorpEW · Entity 3026DirectorMay 02, 2024May 02, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Edwards Lifesciences Corp

Report date May 02, 2024 · Filed May 02, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect4,485.82 Ending reported balance After 2024-05-02 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2024-05-02 · Exercise / conversion · Acquired 29,350 · Balance 33,835.82

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Row 2 · 2024-05-02 · Sale · Disposed 12,207 · Balance 21,628.82

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Row 3 · 2024-05-02 · Sale · Disposed 17,143 · Balance 4,485.82

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2024-05-10Direct0 Reported balance After 2024-05-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-05-02 · Exercise / conversion · Disposed 29,350 · Balance 0

Common StockSEC Table I · non-derivativeIndirectBy Living Trust4,038,377 Reported balance Holding disclosure · report date 2024-05-02 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 4,038,377

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 02, 2024 Filed May 2, 2024 22:05 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-24-005500 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 02, 2024 Filed May 2, 2024 22:05 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 17,143 $84.59 $1,450,126.37
Disclosure

SEC source: 0001225208-24-005500 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 02, 2024 Filed May 2, 2024 22:05 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 12,207 $85.02 $1,037,839.14
Disclosure

SEC source: 0001225208-24-005500 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,628.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 02, 2024 Filed May 2, 2024 22:05 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-24-005500 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
April 04, 2024 Filed Apr 4, 2024 22:26 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-24-004959 · doc4.xml · derivative · entry 7

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,350

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 04, 2024 Filed Apr 4, 2024 22:26 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 16,618 $92.70 $1,540,488.60
Disclosure

SEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F5 · price: This transaction was executed in multiple trades at prices ranging from $92.125 to $93.120. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 04, 2024 Filed Apr 4, 2024 22:26 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 9,820 $91.54 $898,922.80
Disclosure

SEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,103.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F4 · price: This transaction was executed in multiple trades at prices ranging from $91.120 to $92.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 04, 2024 Filed Apr 4, 2024 22:26 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 2,712 $93.72 $254,168.64
Disclosure

SEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,923.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $93.130 to $94.130. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 04, 2024 Filed Apr 4, 2024 22:26 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 200 $94.19 $18,838.00
Disclosure

SEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,635.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $94.185 to $94.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 04, 2024 Filed Apr 4, 2024 22:26 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 00:16 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-24-003505 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,700

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 00:16 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 16,040 $87.05 $1,396,282.00
Disclosure

SEC source: 0001225208-24-003505 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $86.63 to $87.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 00:16 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 13,310 $86.21 $1,147,455.10
Disclosure

SEC source: 0001225208-24-003505 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,525.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $85.62 to $86.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 00:16 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-24-003505 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
February 05, 2024 Filed Feb 5, 2024 23:37 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-24-001597 · doc4.xml · derivative · entry 7

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,050

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 05, 2024 Filed Feb 5, 2024 23:37 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 12,167 $87.55 $1,065,220.85
Disclosure

SEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F5 · price: This transaction was executed in multiple trades at prices ranging from $87.110 to $88.105. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 05, 2024 Filed Feb 5, 2024 23:37 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 9,761 $86.44 $843,740.84
Disclosure

SEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,652.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F4 · price: This transaction was executed in multiple trades at prices ranging from $86.100 to $87.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 05, 2024 Filed Feb 5, 2024 23:37 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 6,422 $88.63 $569,181.86
Disclosure

SEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,413.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $88.210 to $89.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 05, 2024 Filed Feb 5, 2024 23:37 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 1,000 $89.61 $89,610.00
Disclosure

SEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,835.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $89.390 to $90.080. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 05, 2024 Filed Feb 5, 2024 23:37 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
January 05, 2024 Filed Jan 6, 2024 00:19 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-24-000480 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,400

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 05, 2024 Filed Jan 6, 2024 00:19 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 26,850 $72.94 $1,958,439.00
Disclosure

SEC source: 0001225208-24-000480 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $72.41 to $73.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 05, 2024 Filed Jan 6, 2024 00:19 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 2,500 $73.46 $183,650.00
Disclosure

SEC source: 0001225208-24-000480 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,335.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $73.42 to $73.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 05, 2024 Filed Jan 6, 2024 00:19 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-24-000480 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:04 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-23-011072 · doc4.xml · derivative · entry 7

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,750

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:04 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 13,722 $75.12 $1,030,796.64
Disclosure

SEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F5 · price: This transaction was executed in multiple trades at prices ranging from $74.530 to $75.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:04 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 10,600 $74.22 $786,732.00
Disclosure

SEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,207.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F4 · price: This transaction was executed in multiple trades at prices ranging from $73.520 to $74.515. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:04 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 3,200 $73.15 $234,080.00
Disclosure

SEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,807.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $72.510 to $73.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:04 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 1,828 $75.73 $138,434.44
Disclosure

SEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,007.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $75.560 to $75.970. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:04 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
November 06, 2023 Filed Nov 6, 2023 23:33 UTC Edwards Lifesciences Corp EW · Entity 3026 GiftCommon Stock 371,689 $0.00 $0.00
Disclosure

SEC source: 0001225208-23-010019 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Living Trust

Disclosed balance after: 4,038,377

F3 · acquired: In connection with an in-kind transfer of shares from the Reporting Person's 401(k) account to his Living Trust, the remaining 0.7321 of one share was automatically sold by the 401(k) plan administrator at a price of $63.505269 per share, for a total of $46.50, to comply with the plan administrator's policy prohibiting the transfer of a fractional share.

Read SEC document
November 06, 2023 Filed Nov 6, 2023 23:33 UTC Edwards Lifesciences Corp EW · Entity 3026 GiftCommon Stock 371,689 $0.00 $0.00
Disclosure

SEC source: 0001225208-23-010019 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · 401(k)

Disclosed balance after: 0

F3 · acquired: In connection with an in-kind transfer of shares from the Reporting Person's 401(k) account to his Living Trust, the remaining 0.7321 of one share was automatically sold by the 401(k) plan administrator at a price of $63.505269 per share, for a total of $46.50, to comply with the plan administrator's policy prohibiting the transfer of a fractional share.

Read SEC document
November 03, 2023 Filed Nov 6, 2023 23:33 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-23-010019 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 176,100

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 03, 2023 Filed Nov 6, 2023 23:33 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 29,350 $67.18 $1,971,733.00
Disclosure

SEC source: 0001225208-23-010019 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $66.59 to $67.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 03, 2023 Filed Nov 6, 2023 23:33 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-23-010019 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
October 02, 2023 Filed Oct 2, 2023 22:51 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-23-009136 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 205,450

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 02, 2023 Filed Oct 2, 2023 22:51 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 29,350 $68.84 $2,020,454.00
Disclosure

SEC source: 0001225208-23-009136 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $68.39 to $69.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
October 02, 2023 Filed Oct 2, 2023 22:51 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-23-009136 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
September 05, 2023 Filed Sep 5, 2023 23:08 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-23-008709 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 234,800

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 05, 2023 Filed Sep 5, 2023 23:08 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 29,350 $75.86 $2,226,491.00
Disclosure

SEC source: 0001225208-23-008709 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,485.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $75.40 to $76.24. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 05, 2023 Filed Sep 5, 2023 23:08 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-23-008709 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,835.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
August 31, 2023 Filed Aug 31, 2023 21:34 UTC Edwards Lifesciences Corp EW · Entity 3026 GiftCommon Stock 49,766 $0.00 $0.00
Disclosure

SEC source: 0001225208-23-008597 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Living Trust

Disclosed balance after: 3,666,688

Read SEC document
August 31, 2023 Filed Aug 31, 2023 21:34 UTC Edwards Lifesciences Corp EW · Entity 3026 GiftCommon Stock 49,766 $0.00 $0.00
Disclosure

SEC source: 0001225208-23-008597 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,485.82

Read SEC document
August 07, 2023 Filed Aug 7, 2023 23:20 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-23-008065 · doc4.xml · derivative · entry 6

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 264,150

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 07, 2023 Filed Aug 7, 2023 23:20 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 29,050 $79.86 $2,319,933.00
Disclosure

SEC source: 0001225208-23-008065 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,251.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $79.490 to $80.485. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 07, 2023 Filed Aug 7, 2023 23:20 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 300 $80.54 $24,162.00
Disclosure

SEC source: 0001225208-23-008065 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,301.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $80.510 to $80.570. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 07, 2023 Filed Aug 7, 2023 23:20 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionCommon Stock 29,350 $36.75 $1,078,612.50
Disclosure

SEC source: 0001225208-23-008065 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,601.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

Read SEC document
July 05, 2023 Filed Jul 6, 2023 00:13 UTC Edwards Lifesciences Corp EW · Entity 3026 Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative 29,350 $0.00 Strike: $36.75 $0.00
Disclosure

SEC source: 0001225208-23-007306 · doc4.xml · derivative · entry 6

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 293,500

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 05, 2023 Filed Jul 6, 2023 00:13 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 21,728 $90.63 $1,969,208.64
Disclosure

SEC source: 0001225208-23-007306 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,251.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $90.09 to $91.09 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 05, 2023 Filed Jul 6, 2023 00:13 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 7,622 $91.22 $695,278.84
Disclosure

SEC source: 0001225208-23-007306 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,979.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $91.10 to $91.50 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.